title: Twice-daily vs. once-daily inpatient dithranol for psoriasis.
abstract: The aim of this study was to compare the efficacy and tolerability of twice-daily vs. once-daily regimes of dithranol (anthralin) in Lassar's paste. Over a 4-year period, 61 inpatients with stable plaque psoriasis gave informed consent and entered a randomized controlled trial, having twice or once-daily application of dithranol in Lassar's paste as part of otherwise standard Ingram's regime. Primary outcome measurements were time required in hospital, nursing time, changes in total body surface area affected by psoriasis and thickness of a target plaque and in some patients, an assessment of the recurrence of psoriasis. Doctors were blinded as to the regime being used. At entry, mean patient age, lesional surface area and target plaque thickness were comparable in both groups and no patient had received systemic therapy in the preceding 3 months. Forty-two patients completed the study, two (11%) in the twice-daily group withdrawing due to skin irritation or 'burning'. Mean lesional surface area and target plaque thickness were similar in both groups at hospital discharge. Mean (+/- SD) time spent in hospital was not significantly different in each group, being 13.3 (+/- 6.2) days and 13.9 (+/- 4.5) days for the twice-daily and once-daily groups, respectively (P = 0.36). Duration of hospitalization did not correlate with surface area or plaque thickness on admission. Mean (+/- SD) nursing time spent on treatment was significantly greater in the twice-daily group, at 0.82 (+/- 0.33) hours per day compared with 0.51(+/- 0.25) hours per day in the once-daily group. Relapse rate at 6 months was not different between the two groups.
authors.affiliation: Bristol Dermatology Centre, Bristol Royal Infirmary, United Bristol Healthcare Trust, Bristol, UK.
authors.forename: M E
authors.initials: ME
authors.lastname: Kirkup
authors.forename: R A
authors.initials: RA
authors.lastname: Sabroe
authors.forename: G M
authors.initials: GM
authors.lastname: Kavanagh
authors.forename: A M R
authors.initials: AM
authors.lastname: Downs
authors.forename: J E
authors.initials: JE
authors.lastname: Sansom
authors.forename: D A R
authors.initials: DA
authors.lastname: de Berker
authors.forename: M G S
authors.initials: MG
authors.lastname: Dunnill
authors.forename: C T C
authors.initials: CT
authors.lastname: Kennedy
authors.forename: C B
authors.initials: CB
authors.lastname: Archer
mesh_terms: D000279:Administration, Cutaneous; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000875:Anthralin / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000875:Anthralin